News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health, Inc. reports significant revenue increase driven by license agreements for Mytesi® and Canalevia®-CA1, focuses on crofelemer development for rare intestinal indications. Upcoming presentations at ESPGHAN Meeting. Info on investor webcast and CEO's virtual presentation -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
First MVID patient enters active treatment extension phase with liquid crofelemer as adjunctive therapy. Jaguar Health focuses on rare pediatric disease treatment -
